T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.
Metastatic Breast Cancer
DRUG: T-DM1|DRUG: Lapatinib|DRUG: Abraxane
Maximum Tolerable Dose, Maximum tolerated dose (MTD) of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer., approximately 16 weeks
Dose Limiting Toxicities, Describe the dose-limiting toxicity (DLT) associated with Trastuzumab Emtansine in combination with Lapatinib plus Abraxane as assessed by CTCAE v4.0., From date of randomization through study follow up (approximately 16 weeks)|Measure toxicities associated with treatment combination, Describe and measure other toxicities associated with Trastuzumab Emtansine in combination with Lapatinib plus Abraxane as assessed by CTCAE v4.0., From date of randomization through study follow up (approximately 16 weeks)|Anti-tumor activity through imaging, Document anti-tumor activity of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane in metastatic Her2 over-expressed breast cancer as assessed by RECIST 1:1 criteria, approximately 16 weeks from randomization|Plasma pharmacokinetics and pharmacodynamic effect of treatment combination, Determine the plasma pharmacokinetics of Trastuzumab Emtansine in combination with Lapatinib plus Abraxane., Day 1 and 1,2,4,and 24hours
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer. Patients will receive Abraxane on Day 1 of each 1-week cycle and T-DM1 on Day 1 of each 3-week cycle. Patients with take Lapatinib orally daily. Patients will receive the study treatment for 12 weeks.